3-DEUTERO-POMALIDOMIDE
The present application describes 3′-deutero-pomalidomide, deuterated derivatives thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1 . A deuterium-enriched compound of formula I or stereoisomer or pharmaceutically acceptable salt thereof:
wherein: R 1 -R 10 are independently selected from H and D.
2 . A deuterium-enriched compound of claim 1 , or stereoisomer or pharmaceutically acceptable salt thereof, wherein R 1 -R 10 are H.
3 . A deuterium-enriched compound of claim 1 , wherein the compound is of formula I and is selected from:
1
R 1 = D
2
R 1,6-7 = D
3
R 2-3 = D
4
R 2,4 = D
5
R 2-5 = D
6
R 8-10 = D
7
R 2-5,8-10 = D
8
R 2-3,8-10 = D
9
R 2,4,8-10 = D
10
R 1-10 = D
or stereoisomer or pharmaceutically acceptable salt thereof, wherein the non-specified R groups are selected from H and D.
4 . A deuterium-enriched compound of claim 1 , wherein the compound is of formula I and is selected from:
1
R 1 = D
2
R 1,6-7 = D
3
R 2-3 = D
4
R 2,4 = D
5
R 2-5 = D
6
R 8-10 = D
7
R 2-5,8-10 = D
8
R 2-3,8-10 = D
9
R 2,4,8-10 = D
10
R 1-10 = D
or stereoisomer or pharmaceutically acceptable salt thereof, wherein the non-specified R groups are H.
5 . A deuterium-enriched compound of claim 1 , wherein the compound is of formula Ia or stereoisomer or pharmaceutically acceptable salt thereof:
wherein R 1 -R 10 are independently selected from H and D.
6 . A deuterium-enriched compound of claim 5 , or pharmaceutically acceptable salt thereof, wherein the stereoisomeric purity of the compound of formula Ia is at least 33%.
7 . A deuterium-enriched compound of claim 5 , or pharmaceutically acceptable salt thereof, wherein R 1 -R 10 are H.
8 . A deuterium-enriched compound of claim 5 , wherein the compound is of formula Ia and is selected from:
1
R 1 = D
2
R 1,6-7 = D
3
R 2-3 = D
4
R 2,4 = D
5
R 2-5 = D
6
R 8-10 = D
7
R 2-5,8-10 = D
8
R 2-3,8-10 = D
9
R 2,4,8-10 = D
10
R 1-10 = D
or pharmaceutically acceptable salt thereof, wherein the non-specified R groups are selected from H and D.
9 . A deuterium-enriched compound of claim 5 , wherein the compound is of formula Ia and is selected from:
1
R 1 = D
2
R 1,6-7 = D
3
R 2-3 = D
4
R 2,4 = D
5
R 2-5 = D
6
R 8-10 = D
7
R 2-5,8-10 = D
8
R 2-3,8-10 = D
9
R 2,4,8-10 = D
10
R 1-10 = D
or pharmaceutically acceptable salt thereof, wherein the non-specified R groups are H.
10 . A deuterium-enriched compound of claim 1 , wherein the compound is of formula Ib or stereoisomer or pharmaceutically acceptable salt thereof:
wherein R 1 -R 10 are independently selected from H and D.
11 . A deuterium-enriched compound of claim 10 , or pharmaceutically acceptable salt thereof, wherein the stereoisomeric purity of the compound of formula Ib is at least 33%.
12 . A deuterium-enriched compound of claim 10 , or pharmaceutically acceptable salt thereof, wherein R 1 -R 10 are H.
13 . A deuterium-enriched compound of claim 10 , wherein the compound is of formula Ib and is selected from:
1
R 1 = D
2
R 1,6-7 = D
3
R 2-3 = D
4
R 2,4 = D
5
R 2-5 = D
6
R 8-10 = D
7
R 2-5,8-10 = D
8
R 2-3,8-10 = D
9
R 2,4,8-10 = D
10
R 1-10 = D
or pharmaceutically acceptable salt thereof, wherein the non-specified R groups are selected from H and D.
14 . A deuterium-enriched compound of claim 10 , wherein the compound is of formula Ib and is selected from:
1
R 1 = D
2
R 1,6-7 = D
3
R 2-3 = D
4
R 2,4 = D
5
R 2-5 = D
6
R 8-10 = D
7
R 2-5,8-10 = D
8
R 2-3,8-10 = D
9
R 2,4,8-10 = D
10
R 1-10 = D
or pharmaceutically acceptable salt thereof, wherein the non-specified R groups are H.
15 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or pharmaceutically acceptable salt form thereof.
16 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 5 or pharmaceutically acceptable salt form thereof.
17 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 10 or pharmaceutically acceptable salt form thereof.
18 . A method for treating multiple myeloma comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or pharmaceutically acceptable salt form thereof.
19 . A method for treating multiple myeloma comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 5 or pharmaceutically acceptable salt form thereof.
20 . A method for treating multiple myeloma comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 10 or pharmaceutically acceptable salt form thereof.